Dr. Feng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1825 4th St
# L1101
San Francisco, CA 94143Phone+1 415-502-7222
Education & Training
- University of MichiganResidency, Radiation Oncology, 2003 - 2010
- University of MichiganResidency, Radiology-Diagnostic, 2003 - 2005
- Trinity Health Ann Arbor HospitalInternship, Internal Medicine, 2002 - 2003
- Washington University in St. Louis School of MedicineClass of 2002
Certifications & Licensure
- CA State Medical License 2016 - 2025
- MI State Medical License 2002 - 2017
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma Start of enrollment: 2014 May 01
- Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Start of enrollment: 2017 Jan 12
- BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER Start of enrollment: 2018 Apr 27
- Join now to see all
Publications & Presentations
PubMed
- 288 citationsErratum: Integrative Clinical Genomics of Advanced Prostate CancerDan R. Robinson, Eliezer M. Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J. Lonigro
Cell. 2015-07-18 - 150 citationsTranscription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.Jonathan Chou, David A. Quigley, Troy M. Robinson, Felix Y. Feng, Alan Ashworth
Cancer Discovery. 2020-02-18 - 21 citationsCombination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5Adam L. Liss, Eyad Abu-Isa, Maha S. Jawad, Felix Y. Feng, Sean M. Vance
Brachytherapy. 2011-10-01
Journal Articles
- Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the Internationa...Michael J Zelefsky, Matthew R Cooperberg, Brian J Davis, Eric M Horwitz, Martha K Terris, Christopher L Amling, Christopher J Kane, Curtiland Deville, Theodore L Dewee..., JAMA Oncology
- The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetMelody Xu, Felix Y Feng, Corey Speers, Shuang G Zhao, S Laura Chang, Journal of the National Cancer Institute
Press Mentions
- Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley RossJanuary 22nd, 2023
- Who Needs Systemic Treatment with Salvage Radiotherapy? APCCC 2022 Presentation - Brandon MahalAugust 11th, 2022
- Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan SprattAugust 18th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: